Baseline Total Protein as a Prognostic Biomarker for Progression-Free Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
International Journal of Cancer Management · 29.06.2026 · 19 (1)
DOI: 10.5812/ijcm-170651 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer Management, online erschienen am 29.06.2026. Verfasst von Samareh Younesian und 8 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Albumin and the albumin-to-globulin ratio (AGR) are established prognostic markers in multiple myeloma (MM); however, the prognostic value of baseline serum total protein in patients with MM undergoing autologous stem cell transplantation (ASCT) remains unclear.
Objectives
This study investigated the prognostic significance of baseline total protein for progression-free survival (PFS) in patients with MM undergoing autologous stem cell transplantation (ASCT).
Methods
Twenty-one consecutive patients with MM who underwent ASCT between 2023 and 2025 at the Stem Cell Transplant Research Center of Taleghani Hospital were included. Survival outcomes were evaluated using Kaplan-Meier estimates stratified by baseline total protein levels and Cox proportional hazards models. Patients were followed for a median of 19 months (range, 10.5 - 32 months).
Results
Higher baseline total protein was significantly associated with inferior PFS (HR, 2.10; 95% CI, 1.08 - 4.08; P = 0.028). Patients with total protein > 9 g/dL had significantly shorter PFS and 12-month PFS than those with total protein ≤ 9 g/dL (log-rank test; P = 0.008 and P = 0.029, respectively). A trend toward inferior OS was observed (log-rank test; P = 0.052). Elevated total protein was strongly correlated with M-protein and globulin levels and was associated with lower hemoglobin levels and a higher erythrocyte sedimentation rate (ESR).
Conclusions
Higher baseline total protein is associated with inferior PFS in patients with MM undergoing ASCT. Given its simplicity and universal availability, it may serve as a cost-effective and accessible prognostic marker at the time of diagnosis. Larger prospective studies are needed to validate its independent prognostic value.
Zitieren
APA
Younesian, S., Parkhideh, S., Parkhideh, S., Shiraji, S. T., Younesian, O., Shahsavan, S., Asadi, M., Mohammadi, M. H., & Bashash, D. (2026). Baseline Total Protein as a Prognostic Biomarker for Progression-Free Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. International Journal of Cancer Management, 19(1). https://doi.org/10.5812/ijcm-170651
Vancouver
Younesian S, Parkhideh S, Parkhideh S, Shiraji ST, Younesian O, Shahsavan S, et al. Baseline Total Protein as a Prognostic Biomarker for Progression-Free Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. International Journal of Cancer Management. 2026;19(1). doi:10.5812/ijcm-170651
BibTeX
@article{Younesian2026,
author = {Younesian, Samareh and Parkhideh, Sayeh and Parkhideh, Sahar and Shiraji, Sahar Tavakkoli and Younesian, Ommolbanin and Shahsavan, Shaghayegh and Asadi, Marjan and Mohammadi, Mohammad Hossein and Bashash, Davood},
title = {Baseline Total Protein as a Prognostic Biomarker for Progression-Free Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation},
journal = {International Journal of Cancer Management},
year = {2026},
volume = {19},
number = {1},
doi = {10.5812/ijcm-170651}
}
EUVIMED